Dr. Band is a co-inventor of the CytoDel technology and a co-founder of CytoDel. Dr. Band has extensive bench-to-bedside experience in biotechnology startups as former Vice President Research of Biomatrix, an NYSE company acquired by Genzyme in 2000. The products developed by Dr. Band are now marketed by Sanofi, and are among the best selling products in the US for treating osteoarthritis of the knee. Dr. Band has published more than 60 peer-reviewed research studies in both basic and clinical sciences, and has been issued 15 US patents to date. Dr. Band is a Senior Advisor to the Center for Clinical Research, NYU-Hospital for Joint Diseases, and is on the faculty of the Departments of Orthopedic Surgery, Biochemistry and Molecular Pharmacology, NYU School of Medicine.
André Gudger is the Founder and CEO of Eccalon with over twenty years of experience leading middle-market technology companies and
senior positions within the Federal government. From 2011-2017, he served as President Barack Obama's Deputy Assistant Secretary of
Defense for Manufacturing and Industrial Base Policy (MIBP) and the Director of the Office of Small Business Programs. As the Deputy
Assistant Secretary of Defense, André provided detailed analyses of the increasingly global and financially complex industrial supply
chain and took appropriate actions to maintain the health, integrity and technical superiority of the industrial base.
In his many roles, André was also the Defense Department's lead for President Obama's National Network of Manufacturing Innovation, through which he led the establishment of eight manufacturing institutes that focus on additive manufacturing, lightweight metals technology, robotics, and biotechnology. He is credited with reshaping MIBP by creating programs that focus on Business Intelligence, Analytics, and Global Markets to modernize the office's programs and realign its focus areas for the 21st Century.
Previously, he served as the Director of the Office of Small Business Programs, where he acted as the principal advisor to the Secretary of Defense on all matters related to small business, and oversaw more than $120 billion of annual awards to small companies. In his past, André has worked on key technical and financial initiatives with the Federal Deposit Insurance Corporation, Union Bank of Switzerland, AT&T, and founded Solvern Innovations, a cybersecurity solutions company, where he served as its Chairman and Chief Executive Officer. André received his Bachelor of Sciences degree from the University of Maryland at Baltimore County and his M.B.A. from the University of North Carolina at Chapel Hill.
Margery Fischbein is currently Managing Director and Head of Healthcare Investment Banking for Seaport Global, a privately held investment banking firm. Previously, Margery was Head of Healthcare Investment Banking for FBR & Co. and Head of East Coast Biotechnology Investment Banking for JMP Securities. Prior to rejoining the banking industry, Margery held senior corporate positions at two major biotechnology companies-- ImClone Systems and Human Genome Sciences. Margery started her career at Lehman Brothers, JP Morgan Chase and Citigroup, and was a Managing Director for many years at both JP Morgan Chase and Citigroup. Margery has a BA from Harvard University in economics and a MBA from Harvard Business School.
Mr. Remmel is currently a partner of the law firm Pryor Cashman LLP, located in New York City, where he chairs the Banking and Finance practice group. His practice includes corporate and banking financings, issues relating to the Investment Company Act of 1940, and intellectual property and licensing issues, in particular in the biotechnology and biocosmeceutical areas. Mr. Remmel serves as a director of Atossa Genetics Incorporated (NASDAQ: ATOS), a company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975. He currently is a doctoral candidate in the Graduate School of Life Sciences of the University of Utrecht, in the Department of Clinical and Translational Oncology, with a thesis project in hyperplasia and early stage breast cancer.